Drugs Stocks On The Rise With Help From 3 Stocks

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 29 points (-0.2%) at 16,714 as of Tuesday, June 3, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,066 issues advancing vs. 1,889 declining with 193 unchanged.

The Drugs industry currently sits down 1.0% versus the S&P 500, which is down 0.1%. On the negative front, top decliners within the industry include Theravance ( THRX), down 19.4%, Dr Reddy Laboratories ( RDY), down 2.7%, Allergan ( AGN), down 2.5%, AstraZeneca ( AZN), down 1.2% and GlaxoSmithKline ( GSK), down 0.8%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Biomarin Pharmaceutical ( BMRN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Biomarin Pharmaceutical is up $1.74 (3.0%) to $59.74 on average volume. Thus far, 807,280 shares of Biomarin Pharmaceutical exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $57.26-$59.99 after having opened the day at $57.77 as compared to the previous trading day's close of $58.00.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Biomarin Pharmaceutical has a market cap of $8.5 billion and is part of the health care sector. Shares are down 17.6% year-to-date as of the close of trading on Monday. Currently there are 10 analysts who rate Biomarin Pharmaceutical a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Biomarin Pharmaceutical as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, a generally disappointing performance in the stock itself and feeble growth in the company's earnings per share. Get the full Biomarin Pharmaceutical Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Trump's FDA: A Friendlier Biotech Sheriff

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

Why I Hate the FAANGs (but Like Banks and Biotech) for 2017's Second Half

3 Fearless Predictions for the Second Half